Stock Events

Stock Events

Odonate 

$50,000
18
+$0+0% Tuesday 16:27

Statistics

Day High
17,100
Day Low
17,100
52W High
358,000
52W Low
17,100
Volume
1
Avg. Volume
2
Mkt Cap
750M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

25FebExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2024
Q2 2024
Q3 2024
Q4 2024
-2,400
-691.16
1,017.68
2,726.52
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2017
2018
2019
2020
2021
2022
0Revenue
85.88MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ODTCD. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company that develops a wide range of medications, including those for cancer treatment, directly competing with Odonate's focus on cancer therapeutics.
Novartis
NVS
Mkt Cap237.61B
Novartis is a multinational pharmaceutical company that produces drugs across a variety of therapeutic areas, including oncology, making it a competitor in the cancer treatment market.
Merck
MRK
Mkt Cap214.76B
Merck is known for its strong presence in the oncology market, developing treatments that could compete with Odonate's cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is a biopharmaceutical company with a significant focus on cancer drugs, positioning it as a competitor to Odonate Therapeutics.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG, through its pharmaceuticals division, develops cancer treatments, making it a direct competitor in the oncology sector.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca operates in various therapeutic areas, including oncology, and its development of cancer treatments competes with Odonate's offerings.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics, including for cancer, competing with Odonate's cancer focus.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including oncology, which puts it in direct competition with Odonate Therapeutics in the cancer treatment market.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is engaged in the development of medicines for serious medical conditions, including cancer, making it a competitor.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries is a global company that manufactures generic and specialty medicines, including oncology products, competing in the same market as Odonate.

About

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Show more...
CEO
Mr. Kevin C. Tang
Country
US
ISIN
US6760794031

Listings

OTC Link
US
ODTC
OTCM
US
ODTCD

0 Comments

Share your thoughts

FAQ

What is Odonate stock price today?▼
The current price of ODTCD is $50,000 USD — it has increased by +0% in the past 24 hours. Watch Odonate stock price performance more closely on the chart.
What is Odonate stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Odonate stocks are traded under the ticker ODTCD.
What is Odonate market cap?▼
Today Odonate has the market capitalization of 750M
What is Odonate revenue for the last year?▼
Odonate revenue for the last year amounts to 0 USD.
What is Odonate net income for the last year?▼
ODTCD net income for the last year is 85.88M USD.
In which sector is Odonate located?▼
Odonate operates in the Financials sector.
When did Odonate complete a stock split?▼
Odonate has not had any recent stock splits.
Where is Odonate headquartered?▼
Odonate is headquartered in New York, US.